10.05.2016
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler: Sales Growth and Strong Operating Result in the First Quarter
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Quarter Results/Forecast
Eckert & Ziegler: Sales Growth and Strong Operating Result in the First
Quarter
10.05.2016 / 07:45
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 10 May 2016. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE0005659700), a Berlin-based company specializing in isotope technology
for medical, scientific and industrial applications, reported sales of EUR
35.8 million (+6%) in the first quarter of 2016. All segments registered
organic growth. However, the previous year's EBIT level could not quite be
achieved as the prior-year period included a positive currency effect of
EUR 1.3 million, meaning that EBIT declined by EUR 0.9 million to EUR 4.3
million. Earnings after minority interests fell by EUR 0.2 million to EUR
2.5 million, or EUR 0.47 per share.
The Isotope Products segment showed the strongest growth with EUR +1.6
million. At slightly higher costs, EBIT was 5% below the prior year at EUR
3.5 million. As of 2016, the Isotope Products segment includes
Environmental Services which was previously reported under the Others
segment. For comparative purposes, the prior year's figures have also been
adjusted accordingly.
In the Radiation Therapy segment, as expected, sales declined due to the
disposal of the US implant division. Organic growth was achieved with the
new SagiNova(R) tumor irradiation device. After a long time, the segment
achieved balanced operating results once again. One-off effects of EUR -0.3
million each for expenses from the disposal of the US division and a
negative currency effect led to an EBIT of EUR -0.6 million.
Sales grew in the Radiopharma segment, particularly with gallium
generators. The cyclotron division, on the other hand, registered a
downward trend during the whole of 2015. However, this trend reversed in
the first quarter of 2016. Sales and earnings generated with cyclotron
products for diagnosing cancer and Alzheimer's disease almost achieved the
level seen in the first quarter of 2015. EBIT rose by EUR 0.1 million to
EUR 1.5 million.
Operative cash flow increased by 31% to EUR 0.8 million. This effect is due
to a good result for the period, which in contrast to the previous year
does not include non-cash results.
Compared to 2015, more or less constant sales of EUR 140 million are
expected for 2016. Profit is likely to decline to around EUR 1.80 per share
due to the absence of positive one-off effects.
The complete quarterly financial statements can be viewed under:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz116e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str.
10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
---------------------------------------------------------------------------
10.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich
End of News DGAP News Service
---------------------------------------------------------------------------
461707 10.05.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ